Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Elizabeth Galle"'
Autor:
John Bisognano, John E. Schneider, Shawn Davies, Robert L. Ohsfeldt, Elizabeth Galle, Ivana Stojanovic, Thomas F. Deering, JoAnn Lindenfeld, Michael R. Zile
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The study evaluated the cost of baroreflex activation therapy plus guideline directed therapy (BAT + GDT) compared to GDT alone for HF patients with reduced ejection fraction and New York Heart Association Class III or II (with a
Externí odkaz:
https://doaj.org/article/02911598bf1a41c68d89d4c94277a78b
Autor:
Andrew J.S. Coats, William T. Abraham, Michael R. Zile, Joann A. Lindenfeld, Fred A. Weaver, Marat Fudim, Johann Bauersachs, Sue Duval, Elizabeth Galle, Faiez Zannad
Publikováno v:
European Journal of Heart Failure
European Journal of Heart Failure, 2022, 24 (9), pp.1665-1673. ⟨10.1002/ejhf.2573⟩
European Journal of Heart Failure, 2022, 24 (9), pp.1665-1673. ⟨10.1002/ejhf.2573⟩
International audience; Aims: Heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, poor quality of life (QoL) and significant exercise limitation. Sympatho-vagal imbalance has been shown to predic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bdaa3463c305186183ddee4a37f82ac
https://doi.org/10.1002/ejhf.2573
https://doi.org/10.1002/ejhf.2573
Autor:
JoAnn Lindenfeld, Lana Tsao, Faiez Zannad, Samuel F. Sears, Jean Marie Ruddy, Elizabeth Galle, Luanda Grazette, Richa Gupta, Tyson Rogers
Publikováno v:
JACC: Heart Failure
JACC: Heart Failure, Elsevier/American College of Cardiology, 2021, S2213-1779 (21), pp.00060-3. ⟨10.1016/j.jchf.2021.01.012⟩
JACC: Heart Failure, Elsevier/American College of Cardiology, 2021, S2213-1779 (21), pp.00060-3. ⟨10.1016/j.jchf.2021.01.012⟩
International audience; Objectives: The aim of this study was to assess sex differences in the efficacy and safety of baroreflex activation therapy (BAT) in the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial.Background: Patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fcfb266adb80a81bfcff17f3132a63b
https://pubmed.ncbi.nlm.nih.gov/33992562
https://pubmed.ncbi.nlm.nih.gov/33992562
Autor:
Shawn Davies, John E. Schneider, Thomas F. Deering, Elizabeth Galle, Robert L. Ohsfeldt, John D. Bisognano, Ivana Stojanovic, JoAnn Lindenfeld, Michael R. Zile
Publikováno v:
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
Background The study evaluated the cost of baroreflex activation therapy plus guideline directed therapy (BAT + GDT) compared to GDT alone for HF patients with reduced ejection fraction and New York Heart Association Class III or II (with a recent hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b33b14a3bd4b3aceba4cd5b6df4071
https://pubmed.ncbi.nlm.nih.gov/33771104
https://pubmed.ncbi.nlm.nih.gov/33771104
Autor:
JoAnn Lindenfeld, Elizabeth Galle, Tyson Rogers, William T. Abraham, Fred A. Weaver, Faiez Zannad, Michael R. Zile
Publikováno v:
Journal of the American College of Cardiology
Journal of the American College of Cardiology, Elsevier, 2020, 76 (1), pp.1-13. ⟨10.1016/j.jacc.2020.05.015⟩
Journal of the American College of Cardiology, 2020, 76 (1), pp.1-13. ⟨10.1016/j.jacc.2020.05.015⟩
Journal of the American College of Cardiology, Elsevier, 2020, 76 (1), pp.1-13. ⟨10.1016/j.jacc.2020.05.015⟩
Journal of the American College of Cardiology, 2020, 76 (1), pp.1-13. ⟨10.1016/j.jacc.2020.05.015⟩
International audience; Background: This study demonstrated the safety and effectiveness of baroreflex activation therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF).Objectives: The BeAT-HF (Baroreflex Activation Thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d35eeb9d7080205e3f92433c77b596f2
https://hal.univ-lorraine.fr/hal-03020105/file/1-s2.0-S0735109720352980-main.pdf
https://hal.univ-lorraine.fr/hal-03020105/file/1-s2.0-S0735109720352980-main.pdf
Autor:
Tyson Rogers, Faiez Zannad, Elizabeth Galle, Michael R. Zile, William T. Abraham, Todd L. Graves, Fred A. Weaver, JoAnn Lindenfeld
Publikováno v:
American Heart Journal. 204:139-150
Background The Food and Drug Administration (FDA) initiated the Expedited Access Pathway (EAP) to accelerate approval of novel therapies targeting unmet needs for life-threatening conditions. EAP allows for the possibility of initial FDA approval usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::847303e32a91b0d1fa20b78e26a212d8
https://doi.org/10.1016/j.ahj.2018.07.011
https://doi.org/10.1016/j.ahj.2018.07.011
Autor:
Michael Zile, JoAnn Lindenfeld, Fred A. Weaver, Faiez Zannad, Elizabeth Galle, Tyson Rogers, William T. Abraham
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8889937d063b721f6a99bd9ca6e0e106
https://doi.org/10.2139/ssrn.3452105
https://doi.org/10.2139/ssrn.3452105
Autor:
Elizabeth Galle, Leslie A. Saxon, Arthur M. Feldman, Michael R. Bristow, John P. Boehmer, Peter E. Carson, Andrew D. Sumner
Publikováno v:
Congestive Heart Failure. 15:159-164
It is unknown whether statin use improves survival in patients with advanced chronic heart failure (HF) receiving cardiac resynchronization therapy (CRT). The authors retrospectively assessed the effect of statin use on survival in patients with adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aba2eee8c09f71f8a5727081e2e662e
https://doi.org/10.1111/j.1751-7133.2009.00057.x
https://doi.org/10.1111/j.1751-7133.2009.00057.x
Autor:
Brian Olshansky, Leslie A. Saxon, Byron K. Lee, Kent J. Volosin, Fred Ecklund, Elizabeth Galle, Jill Leigh, Thomas Guarnieri, Anupama Rao, Patrick Yong, Gery Tomassoni, Jonathan S. Steinberg, Michael R. Bristow
Publikováno v:
Journal of Cardiovascular Electrophysiology. 20:764-768
Introduction: There are no randomized controlled trial data that evaluate mortality and hospitalization rates in cardiac resynchronization therapy (CRT) recipients based on left ventricular (LV) lead location. We analyzed the event-driven outcomes of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f21af1173908e016225b04aa4dfaac4
https://doi.org/10.1111/j.1540-8167.2009.01444.x
https://doi.org/10.1111/j.1540-8167.2009.01444.x
Autor:
Jerry D. Kennett, Jalal K. Ghali, Leslie A. Saxon, John P. Boehmer, Michael B. Higginbotham, Brian D. Lowes, Michael R. Bristow, Satish Goel, Eugene E. Wolfel, Philip C. Kirlin, Elizabeth Galle, Fred Ecklund, David E. Mann, Teresa De Marco, Lynne E. Wagoner, Arthur M. Feldman, Patrick Yong
Publikováno v:
Journal of Cardiac Failure. 14:9-18
A total of 405 participants in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial were prospectively enrolled in an exercise sub-study designed to study the influence of cardiac resynchronization therapy (CRT) on mea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea2002d601af6f4f8c666027eac48b0e
https://doi.org/10.1016/j.cardfail.2007.08.003
https://doi.org/10.1016/j.cardfail.2007.08.003